THE ROLE OF THE MICROBIOTA-GUT-BRAIN AXIS IN THE PATHOGENESIS AND TREATMENT OF MULTIPLE SCLEROSIS – A REVIEW OF THE LITERATURE
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.5159Keywords:
Multiple Sclerosis, Gut Microbiota, Dysbiosis, Microbiota-Gut-Brain Axis, Short-Chain Fatty Acids, Neuroinflammation, Disease-Modifying Therapies, Immunomodulation, Probiotics, Prebiotics, Fecal Microbiota Tranplantation, Autoimmunity, Central Nervous SystemAbstract
This review examines the bidirectional relationship between the gut microbiome and multiple sclerosis (MS). Analyzing current literature from PubMed and Google Scholar, the paper confirms that MS patients consistently display gut dysbiosis. This is characterized by reduced microbial diversity, a depletion of anti-inflammatory, short-chain fatty acid-producing bacteria, and an overabundance of pro-inflammatory taxa. This imbalance contributes to intestinal barrier dysfunction ("leaky gut"), systemic inflammation, and the activation of neurotoxic T cells, which exacerbates neuroinflammation. Notably, the interaction is reciprocal; common disease-modifying therapies also influence gut microbiota composition. The review concludes that these complex interactions present new opportunities for adjunctive therapies. Emerging evidence supports the potential of microbiome-targeted strategies, including probiotics, prebiotics, dietary changes, and butyrate supplementation, to reduce inflammation and alleviate symptoms, paving the way for more personalized MS management.
Introduction: Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system and a leading cause of neurological disability in young adults. Its pathogenesis involves a complex interplay between genetic susceptibility and modifiable environmental factors. In recent years, the gut microbiota has emerged as a critical regulator of systemic immunity and a potential key modulator of neuroinflammation via the microbiota-gut-brain axis.
Purpose of the work: This review aims to synthesize current evidence on the bidirectional relationship between gut microbiota and multiple sclerosis. It focuses on the molecular mechanisms linking dysbiosis to neuroinflammation, the clinical impact of microbiota alterations in MS patients, and the therapeutic potential of microbiome-targeted interventions.
Materials and methods: A comprehensive analysis of scientific articles available on PubMed and Google Scholar was conducted. The search strategy included combinations of keywords such as "multiple sclerosis", "gut microbiota", "dysbiosis", "short-chain fatty acids", "microbiota-gut-brain axis", "immunomodulation", and "probiotics". Studies published in peer-reviewed journals, including original research, meta-analyses, and clinical trials, were selected for review.
Results: The review confirms that MS patients exhibit significant gut dysbiosis characterized by reduced microbial diversity, depletion of short-chain fatty acid (SCFA)-producing bacteria (e.g., Faecalibacterium, Butyricicoccus), and an increase in pro-inflammatory taxa (e.g., Prevotella). This dysbiosis contributes to increased intestinal permeability ("leaky gut"), systemic low-grade inflammation, and activation of encephalitogenic T cells (Th1/Th17), which exacerbate neuroinflammation and demyelination. Clinical data indicate that over 75% of MS patients report gastrointestinal symptoms, correlating with microbiota alterations. Importantly, the review highlights that standard disease-modifying therapies (e.g., interferon-beta, dimethyl fumarate, ocrelizumab) can themselves modulate gut microbiota composition, suggesting a bidirectional drug-microbiome interaction. Furthermore, emerging evidence supports the therapeutic potential of microbiota-targeted strategies: probiotic supplementation (Lactobacillus, Bifidobacterium) reduces inflammatory markers and improves disability scores; prebiotic fibers (e.g., inulin) enhance SCFA production and attenuate experimental autoimmune encephalomyelitis; dietary interventions alleviate fatigue and improve quality of life; and butyrate, a key SCFA, promotes remyelination. Fecal microbiota transplantation has shown promise in achieving long-term disease stabilization in isolated cases.
References
Lorenzut, S., Negro, I. D., Pauletto, G., Verriello, L., Spadea, L., Salati, C., Musa, M., Gagliano, C., & Zeppieri, M. (2025). Exploring the pathophysiology, diagnosis, and treatment options of multiple sclerosis. Journal of Integrative Neuroscience, 24(1), 25081. https://doi.org/10.31083/JIN25081
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006). Multiple sclerosis—The plaque and its pathogenesis. The New England Journal of Medicine, 354(9), 942–955. https://doi.org/10.1056/NEJMra052130
Shiina, T., Inoko, H., & Kulski, J. K. (2004). An update of the HLA genomic region, locus information and disease associations: 2004. Tissue Antigens, 64(6), 631–649. https://doi.org/10.1111/j.1399-0039.2004.00327.x
Patsopoulos, N. A., Barcellos, L. F., Hintzen, R. Q., Schaefer, C., van Duijn, C. M., Noble, J. A., Raj, T., IMSGC, ANZgene, Gourraud, P. A., Stranger, B. E., Oksenberg, J., Olsson, T., Taylor, B. V., Sawcer, S., Hafler, D. A., Carrington, M., De Jager, P. L., & de Bakker, P. I. W. (2013). Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genetics, 9(11), e1003926. https://doi.org/10.1371/journal.pgen.1003926
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. The Lancet, 391(10130), 1622–1636. https://doi.org/10.1016/S0140-6736(18)30481-1
Ward, M., & Goldman, M. D. (2022). Epidemiology and pathophysiology of multiple sclerosis. Continuum, 28(4), 988–1005. https://doi.org/10.1212/CON.0000000000001136
Ascherio, A., & Munger, K. L. (2016). Epidemiology of multiple sclerosis: From risk factors to prevention—An update. Seminars in Neurology, 36(2), 103–114. https://doi.org/10.1055/s-0036-1579693
Nourbakhsh, B., & Mowry, E. M. (2019). Multiple sclerosis risk factors and pathogenesis. Continuum, 25(3), 596–610. https://doi.org/10.1212/CON.0000000000000725
McKay, K. A., Jahanfar, S., Duggan, T., Tkachuk, S., & Tremlett, H. (2017). Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. Neurotoxicology, 61, 189–212. https://doi.org/10.1016/j.neuro.2016.03.020
Donati, D. (2020). Viral infections and multiple sclerosis. Drug Discovery Today: Disease Models, 32, 27–33. https://doi.org/10.1016/j.ddmod.2020.02.003
Alruwaili, M., & Basri, R. (2025). Environmental and familial risk factors for multiple sclerosis: Insights from a Saudi Arabian cohort. Medicina, 61(4), 730. https://doi.org/10.3390/medicina61040730
Khan, G., & Hashim, M. J. (2025). Epidemiology of multiple sclerosis: Global, regional, national and sub-national-level estimates and future projections. Journal of Epidemiology and Global Health, 15(1), 21. https://doi.org/10.1007/s44197-025-00353-6
GBD 2016 Multiple Sclerosis Collaborators. (2019). Global, regional, and national burden of multiple sclerosis 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(3), 269–285. https://doi.org/10.1016/S1474-4422(18)30443-5
Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., Robertson, N., La Rocca, N., Uitdehaag, B., van der Mei, I., Wallin, M., Helme, A., Angood Napier, C., Rijke, N., & Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis, 26(14), 1816–1821. https://doi.org/10.1177/1352458520970841
Oh, J., Vidal-Jordana, A., & Montalban, X. (2018). Multiple sclerosis: Clinical aspects. Current Opinion in Neurology, 31(6), 752–759. https://doi.org/10.1097/WCO.0000000000000622
Stödberg, L., Olsson, T., Alfredsson, L., & Hedström, A. K. (2026). Determinants and prognostic value of onset symptoms in multiple sclerosis. Journal of Neurology, 273(1), Article 2. https://doi.org/10.1007/s00415-025-13536-9
Sá, M. J. (2012). Physiopathology of symptoms and signs in multiple sclerosis. Arquivos de Neuro-Psiquiatria, 70(9), 733–740. https://doi.org/10.1590/S0004-282X2012000900016
Capone, F., Collorone, S., Cortese, R., Di Lazzaro, V., & Moccia, M. (2020). Fatigue in multiple sclerosis: The role of thalamus. Multiple Sclerosis, 26(1), 6–16. https://doi.org/10.1177/1352458519851247
Meca-Lallana, V., Gascón-Giménez, F., Ginestal-López, R. C., Higueras, Y., Téllez-Lara, N., Carreres-Polo, J., Eichau-Madueño, S., Romero-Imbroda, J., Vidal-Jordana, Á., & Pérez-Miralles, F. (2021). Cognitive impairment in multiple sclerosis: Diagnosis and monitoring. Neurological Sciences, 42(12), 5183–5193. https://doi.org/10.1007/s10072-021-05165-7
Sparaco, M., Lavorgna, L., & Bonavita, S. (2021). Psychiatric disorders in multiple sclerosis. Journal of Neurology, 268(1), 45–60. https://doi.org/10.1007/s00415-019-09426-6
Alcubierre, R., Sánchez-Dalmau, B. F., & Muñoz, S. (2020). La esclerosis múltiple en oftalmología: Más allá de la neuritis óptica [Multiple sclerosis in ophthalmology: Beyond optic neuritis]. Medicina Clínica, 155(2), 70–76. https://doi.org/10.1016/j.medcli.2020.05.017
Wilkins, A. (2017). Cerebellar dysfunction in multiple sclerosis. Frontiers in Neurology, 8, 312. https://doi.org/10.3389/fneur.2017.00312
Zawadka-Kunikowska, M., Rzepiński, Ł., Cieślicka, M., Klawe, J. J., & Tafil-Klawe, M. (2023). Association between daytime sleepiness, fatigue and autonomic responses during head-up tilt test in multiple sclerosis patients. Brain Sciences, 13(9), 1342. https://doi.org/10.3390/brainsci13091342
Todd, L. L., Sivakumar, R., Lynch, S. G., Diebolt, J. H., White, J., & Villwock, J. A. (2023). Longitudinal olfactory patterns in multiple sclerosis: A scoping review and implication for use in management of disease. International Journal of MS Care, 25(3), 131–136. https://doi.org/10.7224/1537-2073.2022-019
Khan, N., & Smith, M. T. (2014). Multiple sclerosis-induced neuropathic pain: Pharmacological management and pathophysiological insights from rodent EAE models. Inflammopharmacology, 22(1), 1–22. https://doi.org/10.1007/s10787-013-0195-3
Ghaaliq Lalkhen, A., Paul Bedford, J., & Devina Dwyer, A. (2012). Pain associated with multiple sclerosis: Epidemiology, classification and management. British Journal of Neuroscience Nursing, 8(5), 267–274. https://doi.org/10.12968/bjnn.2012.8.5.267
Tornic, J., & Panicker, J. N. (2018). The management of lower urinary tract dysfunction in multiple sclerosis. Current Neurology and Neuroscience Reports, 18(8), 54. https://doi.org/10.1007/s11910-018-0857-z
Delaney, K. E., & Donovan, J. (2017). Multiple sclerosis and sexual dysfunction: A need for further education and interdisciplinary care. NeuroRehabilitation, 41(2), 317–329. https://doi.org/10.3233/NRE-172200
Brownlee, W. J., Hardy, T. A., Fazekas, F., & Miller, D. H. (2017). Diagnosis of multiple sclerosis: Progress and challenges. The Lancet, 389(10076), 1336–1346. https://doi.org/10.1016/S0140-6736(16)30959-X
Solomon, A. J. (2019). Diagnosis, differential diagnosis, and misdiagnosis of multiple sclerosis. Continuum, 25(3), 611–635. https://doi.org/10.1212/CON.0000000000000728
Ford, H. (2020). Clinical presentation and diagnosis of multiple sclerosis. Clinical Medicine, 20(4), 380–383. https://doi.org/10.7861/clinmed.2020-0292
Losy, J., Bartosik-Psujek, H., Członkowska, A., Kurowska, K., Maciejek, Z., Mirowska-Guzel, D., Potemkowski, A., Ryglewicz, D., & Stępień, A. (2016). Leczenie stwardnienia rozsianego. Zalecenia Polskiego Towarzystwa Neurologicznego [Treatment of multiple sclerosis: Recommendations of the Polish Neurological Society]. Polski Przegląd Neurologiczny, 12(2), 80–95.
Berkovich, R. R. (2016). Acute multiple sclerosis relapse. Continuum: Lifelong Learning in Neurology, 22(3), 799–814. https://doi.org/10.1212/CON.0000000000000330
Filippini, G., Del Giovane, C., Vacchi, L., et al. (2013). Immunomodulators and immunosuppressants for multiple sclerosis: A network meta-analysis. Cochrane Database of Systematic Reviews, 2013(6), CD008933. https://doi.org/10.1002/14651858.CD008933.pub2
Tramacere, I., Del Giovane, C., Salanti, G., et al. (2015). Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. Cochrane Database of Systematic Reviews, 2015(9), CD011381. https://doi.org/10.1002/14651858.CD011381.pub2
Ontaneda, D., Tallantyre, E., Kalincik, T., Planchon, S. M., & Evangelou, N. (2019). Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. The Lancet Neurology, 18(10), 973–980. https://doi.org/10.1016/S1474-4422(19)30151-6
Adak, A., & Khan, M. R. (2019). An insight into gut microbiota and its functionalities. Cellular and Molecular Life Sciences, 76(3), 473–493. https://doi.org/10.1007/s00018-018-2943-4
Schoultz, I., Claesson, M. J., Dominguez-Bello, M. G., et al. (2025). Gut microbiota development across the lifespan: Disease links and health-promoting interventions. Journal of Internal Medicine, 297(6), 560–583. https://doi.org/10.1111/joim.20089
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 444(7122), 1027–1031. https://doi.org/10.1038/nature05414
Ridaura, V. K., Faith, J. J., Rey, F. E., et al. (2013). Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science, 341(6150), Article 1241214. https://doi.org/10.1126/science.1241214
Gérard, P. (2016). Gut microbiota and obesity. Cellular and Molecular Life Sciences, 73(1), 147–162. https://doi.org/10.1007/s00018-015-2061-5
Cunningham, A. L., Stephens, J. W., & Harris, D. A. (2021). Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut Pathogens, 13(1). https://doi.org/10.1186/s13099-021-00446-0
Han, J. L., & Lin, H. L. (2014). Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective. World Journal of Gastroenterology, 20(47), 17737–17745. https://doi.org/10.3748/wjg.v20.i47.17737
Witkowski, M., Weeks, T. L., & Hazen, S. L. (2020). Gut microbiota and cardiovascular disease. Circulation Research, 127(4), 553–570. https://doi.org/10.1161/CIRCRESAHA.120.316242
Zheng, S., Liu, Z., Liu, H., et al. (2024). Research development on gut microbiota and vulnerable atherosclerotic plaque. Heliyon, 10(4), e25186. https://doi.org/10.1016/j.heliyon.2024.e25186
Zambrano, A. K., Cadena-Ullauri, S., Ruiz-Pozo, V. A., et al. (2024). Impact of fundamental components of the Mediterranean diet on the microbiota composition in blood pressure regulation. Journal of Translational Medicine, 22(1), 417. https://doi.org/10.1186/s12967-024-05175-x
Simpson, C. A., Diaz-Arteche, C., Eliby, D., Schwartz, O. S., Simmons, J. G., & Cowan, C. S. M. (2021). The gut microbiota in anxiety and depression: A systematic review. Clinical Psychology Review, 83, 101943. https://doi.org/10.1016/j.cpr.2020.101943
Yuan, X., Chen, B., Duan, Z., et al. (2021). Depression and anxiety in patients with active ulcerative colitis: Crosstalk of gut microbiota, metabolomics and proteomics. Gut Microbes, 13(1), 1987779. https://doi.org/10.1080/19490976.2021.1987779
Guan, Z. W., Yu, E. Z., & Feng, Q. (2021). Soluble dietary fiber, one of the most important nutrients for the gut microbiota. Molecules, 26(22), 6802. https://doi.org/10.3390/molecules26226802
Parekh, P. J., Oldfield, E. C., & Johnson, D. A. (2018). The effects of sleep on the commensal microbiota. Journal of Clinical Gastroenterology, 52(3), 204–209. https://doi.org/10.1097/MCG.0000000000000965
Wegierska, A. E., Charitos, I. A., Topi, S., Potenza, M. A., Montagnani, M., & Santacroce, L. (2022). The connection between physical exercise and gut microbiota: Implications for competitive sports athletes. Sports Medicine, 52(10), 2355–2369. https://doi.org/10.1007/s40279-022-01696-x
Gałecka, M., Basińska, A. M., & Bartnicka, A. (2018). Znaczenie mikrobioty jelitowej w kształtowaniu zdrowia człowieka—Implikacje w praktyce lekarza rodzinnego. Forum Medycyny Rodzinnej, 12(2), 50–59. https://doi.org/10.5603/fmr.58042
Gomaa, E. Z. (2020). Human gut microbiota/microbiome in health and diseases: A review. Antonie van Leeuwenhoek, 113(12), 2019–2040. https://doi.org/10.1007/s10482-020-01474-7
Alli, S. R., Gorbovskaya, I., Liu, J. C. W., Kolla, N. J., Brown, L., & Müller, D. J. (2022). The gut microbiome in depression and potential benefit of prebiotics, probiotics and synbiotics: A systematic review of clinical trials and observational studies. International Journal of Molecular Sciences, 23(9), 4494. https://doi.org/10.3390/ijms23094494
Zagórska, A., Marcinkowska, M., Jamrozik, M., Wiśniowska, B., & Paśko, P. (2020). From probiotics to psychobiotics—The gut-brain axis in psychiatric disorders. Beneficial Microbes, 11(8), 717–732. https://doi.org/10.3920/BM2020.0063
Wang, H., Lee, I. S., Braun, C., & Enck, P. (2016). Effect of probiotics on central nervous system functions in animals and humans: A systematic review. Journal of Neurogastroenterology and Motility, 22(4), 589–605. https://doi.org/10.5056/jnm16018
Wang, H. X., & Wang, Y. P. (2016). Gut microbiota-brain axis. Chinese Medical Journal, 129(19), 2373–2380. https://doi.org/10.4103/0366-6999.190667
Zhang, X., Wei, Z., Liu, Z., Yang, W., & Huai, Y. (2024). Changes in gut microbiota in patients with multiple sclerosis based on 16S rRNA gene sequencing technology: A review and meta-analysis. Journal of Integrative Neuroscience, 23(7), 127. https://doi.org/10.31083/j.jin2307127
Wang, X., Liang, Z., Wang, S., Ma, D., Zhu, M., & Feng, J. (2022). Role of gut microbiota in multiple sclerosis and potential therapeutic implications. Current Neuropharmacology, 20(7), 1413–1426. https://doi.org/10.2174/1570159X19666210629145351
Altieri, C., Speranza, B., Corbo, M. R., Sinigaglia, M., & Bevilacqua, A. (2023). Gut-microbiota and multiple sclerosis: Background, evidence, and perspectives. Nutrients, 15(4), 942. https://doi.org/10.3390/nu15040942
Kouchaki, E., Tamtaji, O. R., Salami, M., et al. (2017). Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 36(5), 1245–1249. https://doi.org/10.1016/j.clnu.2016.08.015
O’Riordan, K. J., Moloney, G. M., Keane, L., Clarke, G., & Cryan, J. F. (2025). The gut microbiota–immune–brain axis: Therapeutic implications. Cell Reports Medicine, 6(3), 101982. https://doi.org/10.1016/j.xcrm.2025.101982
Calvo-Barreiro, L., Eixarch, H., Ponce-Alonso, M., et al. (2020). A commercial probiotic induces tolerogenic and reduces pathogenic responses in experimental autoimmune encephalomyelitis. Cells, 9(4), 906. https://doi.org/10.3390/cells9040906
Mousavi-Shirazi-Fard, Z., Mazloom, Z., Izadi, S., & Fararouei, M. (2020). The effects of modified anti-inflammatory diet on fatigue, quality of life, and inflammatory biomarkers in relapsing-remitting multiple sclerosis patients: A randomized clinical trial. International Journal of Neuroscience, 131(7), 657–665. https://doi.org/10.1080/00207454.2020.1750398
Li, N., Han, X., Ruan, M., et al. (2024). Prebiotic inulin controls Th17 cells mediated central nervous system autoimmunity through modulating the gut microbiota and short-chain fatty acids. Gut Microbes, 16(1), 2402547. https://doi.org/10.1080/19490976.2024.2402547
Makkawi, S., Camara-Lemarroy, C., & Metz, L. (2018). Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurology: Neuroimmunology & Neuroinflammation, 5(4), e459. https://doi.org/10.1212/NXI.0000000000000459
Chen, T., Noto, D., Hoshino, Y., Mizuno, M., & Miyake, S. (2019). Butyrate suppresses demyelination and enhances remyelination. Journal of Neuroinflammation, 16(1), 165. https://doi.org/10.1186/s12974-019-1552-y
Jangi, S., Gandhi, R., Cox, L. M., et al. (2016). Alterations of the human gut microbiome in multiple sclerosis. Nature Communications, 7, 12015. https://doi.org/10.1038/ncomms12015
Diebold, M., Meola, M., Purushothaman, S., et al. (2022). Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis. Gut Microbes, 14(1), 2147055. https://doi.org/10.1080/19490976.2022.2147055
Coufal, S., Zakostelska, Z. J., Thon, T., et al. (2025). Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome. iScience, 28(12), 113872. https://doi.org/10.1016/j.isci.2025.113872
Lyu, L., Fan, Y., Bryrup, T., et al. (2025). Glucocorticoid-induced changes of the gut microbiota and metabolic markers in healthy young men: Outcome of a randomized controlled trial. Cell Reports Medicine. Advance online publication. https://doi.org/10.1016/j.xcrm.2025.102426
Anani, O., Al Shimi, R., Alkabi, A., et al. (2025). The impact of gut microbiota modulation on disease progression and symptom management in multiple sclerosis (P12-1.004). Neurology, 104(7 Suppl. 1), 5393.
Coufal, S., Zakostelska, Z. J., Thon, T., et al. (2025). Ocrelizumab transiently alters microbiota and modulates immune response depending on treatment outcome. iScience, 28(12), 113872. https://doi.org/10.1016/j.isci.2025.113872
Nemati, M. H., Yazdanpanah, E., Kazemi, R., et al. (2025). Microbiota-driven mechanisms in multiple sclerosis: Pathogenesis, therapeutic strategies, and biomarker potential. Biology, 14(4), 435. https://doi.org/10.3390/biology14040435
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Igor Jętasiewicz, Jakub Sapikowski, Agata Juchniewicz, Julita Jagodzińska, Maria Janiszewska, Iga Kuba, Jakub Idziński, Anna Lubomska, Mikołaj Góralczyk, Martyna Grześkowiak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
